Accord Healthcare Brazil

What Accord Healthcare Brazil does

Accord Healthcare Brazil (operating under the legal name Accord Farma) is a São Paulo-headquartered biopharmaceutical company that develops, markets, and distributes generic and biosimilar medications in Brazil. Founded in 1990 and operating with 51–100 employees, the company is a wholly-owned subsidiary of India's Intas Pharmaceuticals and serves as Intas's commercial vehicle in the Brazilian market, part of a global network spanning more than 85 countries.

The company's portfolio comprises 40+ medications across six therapeutic areas — oncology, hematology, critical care, nephrology, infectiology, and multiple sclerosis — including branded and generic offerings such as Pelgraz (pegfilgrastim biosimilar), Bortyz RTU (ready-to-use bortezomib), Fulvestranto, Paricalcitol, Azzure, Lenalidomida, Micafungina, and Docetaxel. Its principal proprietary technology is PharmaShield®, a registered-trademark protective coating system applied to oncology vials covering from the reinforced base to the vial seal, designed to prevent breakage, leaks, external contamination, and label damage while remaining latex-free. Manufacturing is conducted at Intas Pharmaceuticals' 14 globally certified plants approved by the FDA, EMA, ANVISA, MHRA, and TGA, with the Brazilian entity focused on commercialization rather than local production.

Accord operates an enterprise B2B field-sales model, distributing products directly to hundreds of public and private healthcare institutions across Brazil through both private hospital/clinic contracts and Brazilian government procurement channels. Revenue is generated through one-time institutional sales of generic and biosimilar medications, with pricing not publicly disclosed. The company markets itself through a corporate website, B2B contact center (0800 723 9777), and corporate social media channels (Facebook, Instagram, LinkedIn), without consumer-facing channels.

Name

Accord Healthcare Brazil

Legal name

Accord Farma

Website

https://accordfarma.com.br

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

51–100 employees

Short description

Accord Healthcare Brazil (Accord Farma) is a São Paulo-based biopharmaceutical subsidiary of India's Intas Pharmaceuticals, specializing in generic and biosimilar medications for oncology, hematology, and critical care, distributed to hundreds of healthcare institutions across Brazil.

Ownership category

akta.pro rank

Headquarters

HQ city

São Paulo, SP

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic and Biosimilar Pharmaceutical Products: Accord Farma generates revenue through the sale of generic and biosimilar medications across therapeutic areas including oncology, hematology, critical care, nephrology, infectiology, and multiple sclerosis. The company manufactures and distributes pharmaceutical products to healthcare institutions across Brazil.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Accord Farma (Accord Healthcare Brazil) manufactures, develops, and distributes generic and biosimilar pharmaceutical products in Brazil, with primary focus on oncology, hematology, and critical care therapies. The company supplies more than 40 medications across therapeutic segments including nephrology, infectiology, and multiple sclerosis to public and private healthcare institutions nationwide, leveraging 14 globally certified manufacturing plants through its parent group Intas Pharmaceuticals.

Product overview

Accord Farma is a biopharmaceutical company specializing in generic and biosimilar medications, primarily focused on Oncology, Hematology, and Critical Therapies. The company operates as part of Intas Pharmaceuticals with 14 certified manufacturing plants and presence in over 85 countries. Their portfolio includes 70+ generic pharmaceutical products (Pelgraz, Bortyz RTU, Fulvestranto, Paricalcitol, Azzure, Apixabana, Cloridrato de Gencitabina, Carboplatina, Docetaxel, Oxaliplatina, Paclitaxel, Bortezomibe, Lenalidomida, Micafungina, and many others) across therapeutic areas including oncology, hematology, nephrology, infectiology, multiple sclerosis, and critical therapies. They also offer PharmaShield technology, a protective coating system for their injectable oncology products that provides breakage protection, contamination prevention, and label protection.

Differentiator

Problem solved

Functional benefit

Brands

• PharmaShield: A protective coating technology applied to Accord's oncology products, covering from reinforced base to vial cap. Protects against breakage, leaks, external contamination, and label information. Latex-free with PVC-free reinforced base for greater stability.
• Pelgraz
• Bortyz
• Fulvestranto
• Paricalcitol

Products and services

• Azzure (Azacitidina)
• Apixabana
• Ácido Zoledrônico
• Bleomicina
• Bicalutamida (Bycal 150mg)
• Bissulfato de Clopidogrel
• Bussulfano
• Brecila
• Bortezomibe (Bortyz RTU)
• Bicalutamida
• Cloridrato de Gencitabina
• Cloridrato de Topotecana
• Carboplatina
• Cloridrato de Sertralina
• Cloridrato de Palonosetrona
• Cloridrato de Irinoteano Tri-hidrato
• Cloridrato de Epirrubicina
• Clopidogrel
• Citarabina
• Cisplatina
• Dasatinibe
• Daptomicina (DOPCYM)
• Decitabina
• Docks
• Docetaxel
• Daptomicina
• Enzalutamida (Nindev)
• Exemestano
• Fampridina
• Fil (Filgrastim)
• Fulvestranto
• Fosaprepitanto Dimeglumina
• Fluoruracila
• Gencitabina
• Hytas
• Lenalidomida (Lyone)
• Letrozol
• Micafungina (Mycafrem)
• Micofenolato de Sódio
• Micofenolato de Mofetila
• Esilato de Nintedanibe
• Neugrast
• Olmesartana Medoxomila
• Oxaliplatina
• Pemtryx
• Pelgraz
• Paricalcitol
• Palocyt
• Paclitaxel
• Rosuvastatina Cálcica
• Risperidona
• Sugamadex Sódico
• Sondelbay (Teriparatida)
• Tigeciclina
• Telmisartana
• Tosilato de Sorafenibe
• Taxontas
• Tadalafila
• Voriconazol
• Cisatracúrio
• Azacitidina
• Bortezomibe
• Lyone (Lenalidomida)
• Micafungina
• Nindev (Enzalutamida)

Quantifiable outcome

• Present in 85+ countries globally
• +3 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Intas PharmaceuticalscoreOthersAccord Farma is an integral part of Intas Pharmaceuticals, a global biopharmaceutical company. Accord operates as the subsidiary/brand for Intas in over 85 countries worldwide, leveraging Intas's 14 certified manufacturing plants and global distribution network to produce and distribute biosimilar and generic medications.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Eurofarma Laboratórios: Major Brazilian pharma company with strong hospital, oncology, and generics footprint. Competes with Accord Farma for the same institutional buyers and tenders across Latin America.
• Aché Laboratórios: Brazilian pharma with generics and branded hospital products, including oncology and critical care. Comparable therapeutic-area coverage and Brazilian distribution depth.
• Libbs Farmacêutica: Brazilian pharma with strong oncology, hematology, and specialty hospital portfolio. Directly comparable in therapeutic focus and hospital-channel GTM.
• EMS Pharma: Brazil's largest generics manufacturer with broad oncology and hospital portfolio. Directly comparable to Accord Farma in both generic/biosimilar manufacturing and B2B hospital distribution within Brazil.
• Biolab Farmacêutica: Brazilian pharma with a significant hospital and specialty franchise including oncology. Competes for similar public and private hospital contracts.

Broad incumbents

• Viatris (Brazil): Global generics giant (Mylan/Upjohn merger) with a substantial Brazilian presence. Overlaps with Accord Farma in generics and biosimilars across multiple therapeutic areas.
• Teva Pharmaceutical (Brazil): Multinational generics leader with Brazil operations, including oncology and specialty products. Comparable multinational generic and biosimilar portfolio.
• Sandoz (Brazil): Global generics and biosimilars leader with Brazilian operations. Comparable as a multinational generic/biosimilar competitor in oncology, hematology, and critical care.

Others

• Intas Pharmaceuticals (Parent): Parent company of Accord Farma, providing the 14 globally certified plants and product dossiers. Relevant as the strategic supplier and ultimate decision-maker for Accord Farma's portfolio.

Emerging players

• Aurobindo Pharma (Brazil): Indian multinational generics manufacturer with growing Brazilian operations. Comparable as an India-based parent-affiliated generic distributor expanding in Brazil.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Customer concentration

• Facebookfacebook.com/accordfarma
• Instagraminstagram.com/accordfarma
• LinkedInlinkedin.com/company/accord-farma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accord Healthcare Brazil